Humana's 2024 earnings reveal revenue growth but major structural issues impacting profitability. Learn about risks, new ...
JuliaHub simplifies complex pharmaceutical workflows by integrating analytics such as modeling and simulation in pharmacometrics. Unlike fragmented systems, it ensures seamless transitions between ...
2d
Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that ...
In a relatively short time, RFK Jr. has forced America to begin to recognize that the food choices they make have significant ...
Hosted on MSN6d
Bristol-Myers Squibb (NYSE:BMY) Posts Better-Than-Expected Sales In Q4 But Full-Year Sales Guidance Misses ExpectationsBiopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced in Q4 CY2024, with sales up 7.5% year on year to $12.34 ...
The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback